Calendario de promoción GRAIL, LLC
Horario avanzado
gráfico sencillo
Acerca de la empresa GRAIL, LLC
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.| IPO date | 2024-06-25 |
|---|---|
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://grail.com |
| Цена ао | 26.92 |
| Cambio de precio por día: | 0% (29.74) |
|---|---|
| Cambio de precio por semana.: | -7.32% (32.09) |
| Cambio de precio por mes: | -43.44% (52.58) |
| Cambio de precio en 3 meses.: | +30.78% (22.74) |
| Cambio de precio en seis meses: | +111.82% (14.04) |
| Cambio de precio desde principios de año.: | +62.07% (18.35) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
|---|---|---|---|
| Principal Healthcare Innovators ETF | 0.04203 | 618.5 | 0.8416 |
| Future Tech ETF | 0.04203 | 426.34 | 0.8416 |
| iShares Russell Mid-Cap Value ETF | 0.00401 | 18.01 | 2.03934 |
iShares Russell Midcap ETF
|
0.00308 | 20.77 | 1.71565 |
iShares Russell 1000 Value ETF
|
0.00147 | 17.45 | 2.15361 |
| iShares U.S. Tech Independence Focused ETF | 0.00083 | 34.94 | 0.84412 |
| iShares Russell 3000 ETF | 0.00067 | 24.83 | 1.43482 |
| 0.01 | 165.83 | 1.41 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Mr. Robert P. Ragusa | CEO & Director | 1960 (65 años) | |
| Dr. Joshua J. Ofman M.D., M.S.H.S | President | 1965 (60 años) | |
| Mr. Aaron Freidin | Chief Financial Officer | ||
| Mr. Paul Ciccolella | Senior VP of Global Development & Operations | ||
| Ms. Amoolya Singh Ph.D. | Senior VP of Research & Chief Scientific Officer | ||
| Mr. Abram Barth J.D., M.P.H. | General Counsel | ||
| Ms. Julie Currie | Chief People Officer | ||
| Mr. Rodger Currie | VP and Head of Government Affairs & Alliance Development | ||
| Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng | President Biopharma Business & Europe | ||
| Dr. Satnam Alag Ph.D. | Senior VP of Software Engineering & Chief Security Officer |
DIRECCIÓN: United States, Menlo Park, 1525 O’Brien Drive - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://grail.com
Sitio web: https://grail.com
